Skip to main content
ASTRO 2024 Main banner
Icon Legend
Presentation Icons
Event Add-on
Event Add-on
In Person Only
In Person Only
Off-site Event
Off-site Event
Location: Marriott Marquis
Location: Marriott Marquis
Back

Daniel Spratt, MD

University Hospitals Seidman Cancer Center
Beachwood, OH, United States

Daniel Spratt, MD, is the Vincent K. Smith Professor and Chairman of the Department of Radiation Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine. Dr. Spratt completed his medical training at Vanderbilt University and residency training in Radiation Oncology at Memorial Sloan Kettering Cancer Center. He joined the faculty at the University of Michigan in 2015 and became a tenured Professor by 2020. While at the University of Michigan he was the Chief of the Genitourinary Radiotherapy Program, Associate Chair of Clinical Research, Fellowship Director, the Laurie Snow Endowed Research Professor, Director of Spine Oncology and co-Chair of the Genitourinary Clinical Research Team for the Rogel Cancer Center. Dr. Spratt is an international expert in prostate cancer and serves as the Chair of the Intact Prostate Cancer Subcommittee within NRG Oncology and is a member of the National Cancer Institute’s Genitourinary Steering Committee. He serves as an invited biomarker for the NCCN Prostate Cancer Guidelines and is the first standing member to the FDAs Oncology Drug Advisory Committee. He runs an NIH funded translational research team focused on the development and validation of prognostic and predictive biomarkers, has published over 400 peer-reviewed manuscripts, and has served as the principal investigator on numerous national and international clinical trials. He has mentored over 50 students, residents, fellows, and faculty, and has received numerous teaching and mentorship awards.

Disclosures:

  • Employment: University Hospitals Seidman Cancer Center:Chair and Professor:Employee
  • Compensation: Astellas: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: ongoing ;AstraZeneca: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: 6/1/2023 ;Bayer: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: ongoing ;Janssen: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: ongoing ;Myovant/Pfizer: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: ongoing ;Novartis: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: 6/1/2022 ;Boston Scientific: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Consultant, Honoraria-End Date: ongoing ;Elekta: Consultant, Honoraria-End Date: 6/1/2022 ;Gammatile: Consultant, Honoraria-End Date: 2/1/2022 ;varian: Honoraria-End Date: 7/1/2022
  • Ownership: none
  • Leadership: none

Presentation(s):